PGR and neoplasm: For the 15% triple-negative breast cancer (TNBC) patients whose tumor does not overexpress estrogen receptor, progesterone receptor, or HER2, they can only be treated with chemotherapy and surgery, have a worse prognosis, and are more likely to relapse [22].